Integrative transcriptomic and experimental analyses prioritize TPT1 as a PANoptosis-associated candidate molecular

Shijie Dong1, Min Wang2, Chen Liang1

  • 1Department of Neurology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Abstract

Insights

Tumor protein, translationally controlled 1 (TPT1) is a potential molecular marker for early sarcopenia detection. Lower TPT1 levels correlate with aging muscle, inflammation, and cell-death pathways, suggesting its role in sarcopenia pathogenesis.

Area of Science:

  • Gerontology
  • Molecular Biology
  • Immunology

Background:

  • Sarcopenia lacks sensitive molecular markers for early detection.
  • The role of integrated inflammatory cell-death programs in sarcopenia is unclear.
  • PANoptosis, integrating apoptosis, pyroptosis, and necroptosis, offers a framework to study aging skeletal muscle.

Purpose of the Study:

  • To identify molecular markers for early sarcopenia detection.
  • To investigate the association between PANoptosis and sarcopenia.
  • To explore the role of TPT1 in aging skeletal muscle.

Main Methods:

  • Integrated four bulk-transcriptomic datasets and validated with an external cohort.
  • Performed gene set enrichment analysis, machine learning feature selection (LASSO, random forest, XGBoost), nomogram, and ROC analyses.
  • Conducted CIBERSORT immune-cell deconvolution, snRNA-seq, and assessed TPT1 expression in mouse and cell models.

Main Results:

  • Identified 47 overlapping genes between differentially expressed genes and PANoptosis-associated genes, enriched in inflammatory and cell-death pathways.
  • Machine learning algorithms identified NTRK1, TPT1, and TRAP1 as key discriminators, with TPT1 showing strong diagnostic potential (AUC > 0.75).
  • Lower TPT1 expression in aging muscle correlated with inflammatory, oxidative stress, and cell-death pathways; reduced TPT1 protein was observed in muscle-wasting models.

Conclusions:

  • TPT1 is a promising candidate molecular marker for sarcopenia.
  • The study provides biological context for TPT1's role in aging muscle but requires further validation.
  • Prospective clinical studies are needed to confirm TPT1's specificity and causality in sarcopenia.